Infertility in womenPelvic inflammatory disease; Polycystic ovaries
An in-depth report on the causes, diagnosis, treatment, and prevention of female infertility.
Risk factors for female infertility include:
- Age. Fertility begins to decline when a woman reaches her mid-30s, and rapidly declines after her late 30s.
- Weight. Extreme weight levels, either high or low, can contribute to infertility.
- Smoking. Cigarette smoking can impair a woman’s fertility.
- Alcohol. More than 2 drinks a day may impair a woman’s fertility.
Infertility may be caused by an underlying medical condition that damages the fallopian tubes, interferes with ovulation, or causes hormonal complications. These medical conditions include:
- Pelvic inflammatory disease
- Polycystic ovary syndrome
- Premature ovarian failure
- Uterine fibroids
If you have been unable to conceive after 1 year of unprotected sex, talk with your doctor about having your fertility evaluated. Fertility testing should especially be performed if a woman is over 35 years old or if either partner has known risk factors for infertility. An analysis of the man's semen should be performed before the female partner undergoes any invasive testing.
Treatment for infertility should first address any underlying medical condition that may be contributing to fertility problems. If this step does not restore fertility, there are several treatment approaches:
- Lifestyle measures (such as maintaining a healthy weight, quitting smoking, limiting alcohol consumption, timing sexual activity with regard to the ovulation cycle)
- Drugs to induce ovulation, such as clomiphene or gonadotrophins
- Assisted reproductive technologies (ART), such as in vitro fertilization (IVF)
Lifestyle Tips for Optimizing Natural Fertility
In 2013, the American Society for Reproductive Medicine issued recommendations for how couples can increase the likelihood of achieving pregnancy (this applies to couple who have no evidence of infertility):
- For women who have regular menstrual cycles, having sexual intercourse every 1 - 2 days during the “fertile window” (the 6 days leading up to and including ovulation) can increase the chances for conception.
- Couples should avoid using water-based sexual lubricants because they can damage the sperm’s ability to swim. Instead, try mineral oil, canola oil, or commercial “fertility friendly” labeled products.
- There’s no evidence that certain sexual positions, or resting after sex, boosts fertility or increases the odds for getting pregnant.
Fertility Preservation for Cancer Patients
In 2013, the American Society for Clinical Oncology (ASCO) released updated guidelines on fertility preservation for patients with cancer. ASCO recommends:
- Begin the conversation with your health care team as early as possible, before you begin cancer treatment. Timing is very important.
- For women, ASCO recommend embryo and egg freezing (cryopreservation) as the most well-established methods for fertility preservation. For men, sperm cryopreservation is the only established method. Other cryopreservation methods are considered experimental and are not recommended.
- Some women who are undergoing pelvic radiation or gynecological surgery may be candidates for certain procedures that can help conserve fertility. They should discuss their options with their doctors.
Infertility is the failure of a couple to become pregnant after one year of regular, unprotected intercourse. In both men and women the fertility process is complex.
Infertility affects about 10% of all couples. About a third of infertility problems are due to female infertility, and another third are due to male infertility. In the remaining cases, infertility affects both partners or the cause is unclear. Although this report specifically addresses infertility in women, it is important for the male partner to be tested at the same time.
The Female Reproductive System
The primary organs and structures in the reproductive system are:
- The uterus is a pear-shaped organ located between the bladder and lower intestine. It consists of two parts, the body and the cervix.
- The cervix is the lower portion of the uterus. It has a canal opening into the vagina with an opening called the os, which allows menstrual blood to flow out of the uterus into the vagina.
- Leading off each side of the uterus are two tubes known as the fallopian tubes. Near the end of each tube is an almond-sized organ called an ovary. Women have two ovaries, one located on each side of the uterus.
- Ovaries are the "factories" for egg production. Ovaries contain hundreds of thousands of follicles (from folliculus, meaning "sack" in Latin). Each ovarian follicle houses an immature egg. .
- At the beginning of a menstrual cycle, several ovarian follicles begin to develop, but only one follicle becomes dominant. The dominant follicle produces a mature egg, which is released at the time of ovulation. Usually, only one egg is released. (Multiple births occur if two or more eggs are released and fertilized. Fraternal twins develop from two separate eggs that are fertilized by two separate sperm. Identical twins develop from a single fertilized egg that splits to form two embryos.)
The uterus is a hollow muscular organ located in the female pelvis between the bladder and rectum. The ovaries produce the eggs that travel through the fallopian tubes. Once the egg has left the ovary it can be fertilized and implant itself in the lining of the uterus. The main function of the uterus is to nourish the developing fetus prior to birth.
The menstrual cycle is regulated by the complex surge and fluctuations of many different reproductive hormones, which work together to prepare a women’s body for pregnancy.
The hypothalamus (an area in the brain) and the pituitary gland control six important hormones:
- Gonadotropin-releasing hormone (GnRH) is released by the hypothalamus.
- GnRH stimulates the pituitary gland to produce follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
- The female hormones estrogen and progesterone, and the male hormone testosterone are secreted by the ovaries at the command of FSH and LH.
The Menstrual Cycle
During a woman’s monthly menstrual cycle, her body prepares for conception and pregnancy. The average menstrual cycle is about 28 days but anywhere from 21 days to 35 days is considered normal. The menstrual cycle is divided into three phases: Follicular, Ovulatory, and Luteal.
Follicular Phase. The follicular phase begins with the first day of menstrual bleeding:
- At the start of the follicular phase, estrogen and progesterone levels are at their lowest point. This causes the uterine lining to break down and shed.
- At the same time, the hypothalamus produces gonadotropin-releasing hormone GnRH, which stimulates the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH and LH trigger the production of estrogen.
- As FSH levels increase, they stimulate the growth and maturation of eggs in the follicles. About 15 - 20 follicles are stimulated, but only one follicle continues to mature.
- The dominant follicle produces estrogen. The other follicles stop growing and disintegrate.
Ovulatory Phase. The ovulatory phase occurs halfway through the menstrual cycle (about 14 days after the start of the follicular phase.) Ovulation, the critical process for conception, occurs during the ovulatory phase. A woman’s fertile period starts about 3 - 5 days before ovulation and ends 24 - 48 hours after it. During the ovulatory phase:
- The increase in estrogen from the dominant follicle triggers a surge in LH. As estrogen levels rise, they prompt the cervix to secrete more mucus to help nourish and propel sperm to the egg.
- The LH surge signals the dominant follicle to burst and release the developed egg into the fallopian tube. The release of the egg is called ovulation. Once in the fallopian tube, the egg is in place for fertilization.
- The egg can live for 24 - 48 hours after being released. (Sperm can live for 3 - 5 days.) A woman is most likely to get pregnant if sex occurs in the 3 - 5 days before ovulation or on the day of ovulation.
Luteal Phase. The luteal phase begins immediately after ovulation and ends when the next menstrual period starts. The luteal phase lasts about 12 - 16 days. During the luteal phase:
- After releasing the egg, the ruptured follicle closes and forms corpus luteum, a yellow mass of cells that provide a source of estrogen and progesterone during pregnancy. These hormones help the uterine lining to thicken and prepare for the egg’s implantation.
- If the egg is fertilized by a sperm cell, it implants in the uterus and pregnancy begins.
- If fertilization does not occur, the egg breaks apart. The corpus luteum degenerates, and estrogen and progesterone levels drop.
- Finally, the thickened uterine lining sloughs off and is shed along with the unfertilized egg during menstruation. The menstrual cycle begins again.
Fertilization and Pregnancy
Conception occurs when an egg is fertilized by a sperm. The so-called "fertile window" is about 6 days long. It starts about 5 days before ovulation and ends the day of ovulation. Fertilization occurs as follows:
- Sperm can survive for 3 - 5 days after they enter the fallopian tube. The egg survives 24 - 48 hours unless it is fertilized by a sperm.
- The fertilized egg is called a zygote. The zygote immediately begins to divide until it becomes a ball of cells known as a blastocyst.
- The blastocyst moves from the fallopian tube into the uterus where it is implanted in the uterine lining. Implantation takes place about 6 - 10 days after fertilization. Implantation is when pregnancy begins.
- The inner cells of the blastocyst become the embryo, which develops into the fetus. The outer cells of the blastocyst become the placenta. The placenta is a thick blanket of blood vessels that nourishes the fetus as it develops.
- The developing embryo produces and secretes the protein human chorionic gonadotropin (hCG), which helps signal the corpus luteum (the yellow tissue formed from the ruptured follicle) to continue to produce estrogen and progesterone. HCG is the hormone detected by pregnancy tests. After about 10 weeks, the placenta takes over production of progesterone and estrogen, and the corpus luteum degenerates.
Typical Menstrual Cycle
Typical No. of Days
Follicular (Proliferative) Phase
Cycle Days 1 - 6: Beginning of menstruation to end of blood flow.
Estrogen and progesterone start out at their lowest levels.
FSH levels rise to stimulate maturity of follicles. Ovaries start producing estrogen and levels rise, while progesterone levels remains low.
Cycle Days 7 - 13: The endometrium (the inner lining of the uterus) thickens to prepare for egg implantation.
Cycle Day 14:
Surge in LH. Largest follicle bursts and releases egg into fallopian tube.
Luteal (Secretory) Phase, also known as the Premenstrual Phase
Cycle Days 15 - 28:
Ruptured follicle develops into corpus luteum, which produces progesterone. Progesterone and estrogen stimulate blanket of blood vessels to prepare for egg implantation.
If fertilization occurs:
Fertilized egg attaches to blanket of blood vessels that supplies nutrients for the developing placenta. Corpus luteum continues to produce estrogen and progesterone.
If fertilization does not occur:
Corpus luteum deteriorates. Estrogen and progesterone levels drop. The blood vessel lining sloughs off and menstruation begins.
Most cases of female infertility are due to medical conditions that cause:
- Ovulation problems
- Blocked fallopian tubes
- Structural problems in the reproductive system
- Problems with quality of cervical mucus or eggs
Ovulation is the release of the egg that occurs during the monthly menstrual cycle. Problems that affect ovulation, and the hormones involved with ovulation, are the most common cause of female infertility. They include:
- Polycystic Ovarian Syndrome (PCOS). Women with PCOS do not ovulate regularly and they experience infrequent or absent menstrual cycles. In PCOS, the ovaries produce excessive amounts of androgens (male hormones), particularly testosterone. Increased androgen production results in high levels of luteinizing hormone (LH) and low levels of follicle-stimulating hormone (FSH), so that follicles are prevented from producing a mature egg. Without egg production, the follicles swell with fluid and form into cysts. The elevated levels of androgens can also cause obesity, facial hair, and acne. PCOS poses a high risk for insulin resistance, which is associated with type 2 diabetes.
- Premature Ovarian Failure (Early Menopause). Premature ovarian failure is the early depletion of follicles before age 40, which, in most cases, leads to premature menopause. It is often caused by hormonal issues such as adrenal, pituitary, or thyroid gland deficiencies. It can also be caused by genetic disorders such as Turner syndrome and fragile X syndrome. Certain types of autoimmune disorders (type 1 diabetes, systemic lupus erythematosus, Addison’s disease) are associated with premature ovarian failure. Radiation and chemotherapy cancer treatments can also cause early menopause.
- Hormonal Imbalances. Imbalances with reproductive hormones such as FSH, LH, estrogen, and progesterone can interfere with ovulation.
Blocked Fallopian Tubes
A blocked fallopian tube can prevent sperm from reaching and fertilizing the egg. Blockage in the fallopian tubes can also prevent a fertilized egg from traveling to the uterus for implantation. Conditions that can block or damage fallopian tubes include:
- Pelvic Inflammatory Disease (PID). PID refers to infection in the pelvic are and reproductive tract, including the fallopian tubes. PID is a complication of bacterial infection. The most common causes are sexually transmitted diseases, especially chlamydia and gonorrhea. In addition to infertility, PID can increase the risk for ectopic pregnancy, where the embryo implants in the fallopian tube or another location outside of the uterus.
- Endometriosis. Endometriosis is a condition in which cells that line the uterus grow in areas outside of the uterus, such as the ovaries. Endometriosis rarely causes a complete inability to conceive, but it can reduce fertility both directly and indirectly. Implants in the fallopian tubes may block the egg’s passage, while implants that occur in the ovaries can prevent the release of the egg. Severe endometriosis can form bands of scar tissue (adhesions) between the uterus, ovaries, and fallopian tubes that prevent egg transfer.
- Uterine or Abnormal Scarring. Adhesions can be caused by conditions besides endometriosis. Adhesions that form after abdominal or pelvic surgery or infection can restrict the movement of ovaries and fallopian tubes and may cause infertility. Asherman syndrome, for example, is scarring in the uterus that may be caused by surgery, repeated injury, or unknown factors.
- Uterine Fibroids. Uterine fibroids may contribute to infertility by blocking the fallopian tube, or by distorting the shape of the uterine cavity. Fibroids may also impair blood flow to the uterine lining.
Other Causes of Female Infertility
Other possible causes of female infertility include:
- Elevated Prolactin Levels. Prolactin is a hormone produced in the pituitary gland that stimulates breast development and milk production in association with pregnancy. High levels of prolactin (hyperprolactinemia) reduce gonadotropin hormones and inhibit ovulation. Hyperprolactinemia in women who are not pregnant or nursing can be caused by an underactive thyroid gland or pituitary adenoma. (Pituitary adenomas are benign tumors that secrete prolactin.) Some drugs, including oral contraceptives and some antipsychotic drugs, can also elevate levels of prolactin.
- Congenital Structural Abnormalities. Congenital reproductive tract abnormalities may cause infertility. These malformations typically affect the uterus or vagina. Daughters born to women who took the drug diethylstilbestrol (DES) during pregnancy are at increased risk of having uterine or fallopian tube structural abnormalities associated with infertility. Some women who are born with uterine or other reproductive tract malformations are still able to have successful pregnancies. Surgery can correct some of these problems.
- Cervical Mucus. Low amounts of cervical mucus or poor quality cervical mucus can contribute to infertility. Cervical mucus problems may be related to hormonal imbalances, prior surgeries, or certain medications.
- Egg Quality. As women age, the number and quality of their eggs diminish. Younger women can also have problems with egg quality, usually because of medical conditions or treatments that impair the ovaries. Radiation and chemotherapy cancer treatments, for example, can damage ovaries and affect egg development.
In the U.S., about 11% of women ages 15 - 44, or about 6.7 million women, have problems getting pregnant or carrying a baby to term.
Fertility declines as a woman ages. Fertility begins to decline when a woman reaches her mid-30s, and rapidly declines after her late 30s. As a woman ages, her ovaries produce fewer eggs. In addition, the quality of the eggs is poorer than those of younger women. Older women have a higher risk for eggs with chromosomal abnormalities, which increase the risk for miscarriage and birth defects. Older women are also more likely to have health problems that may interfere with fertility.
The American Society of Reproductive Medicine recommends that a woman over age 35 should consider consulting a reproductive specialist if she has attempted unsuccessfully to conceive for 6 months
Although most of a woman's estrogen is manufactured in her ovaries, smaller amounts are produced by fat cells, which transform male hormones produced by the adrenal glands into estrogen. Because a normal hormonal balance is essential for the process of conception, extreme weight levels (either high or low) can contribute to infertility.
Being Overweight. Being overweight or obese can contribute to infertility in various ways. Obesity is also associated with polycystic ovarian syndrome (PCOS), an endocrinologic disorder that can cause infertility.
Being Underweight. Body fat levels that are significantly below normal can completely shut down the reproductive process. Women at risk include:
- Women with eating disorders, such as anorexia or bulimia nervosa.
- Women on very low-calorie or restrictive diets are at risk, especially if their periods are irregular.
- Strict vegetarians might have difficulties if they lack important nutrients, such as vitamin B12, zinc, iron, and folic acid.
- Marathon runners, dancers, and others who exercise very intensely.
Cigarette smoking can harm a woman’s ovaries and contribute to a decrease in eggs. Studies show that women who smoke are more likely to reach menopause earlier than women who do not smoke. And, studies indicate that smokers require more IVF cycles to conceive than nonsmokers. Nonsmokers exposed to excessive passive cigarette smoke may have similar risks. Some evidence also suggests that marijuana use may impair a woman’s fertility. .
Alcohol and Caffeine Use
Alcohol and caffeine use may contribute to infertility. In any case, doctors recommend that women trying to conceive limit themselves to 1 alcoholic drink a day. For caffeine, 1 – 2 cups of coffee a day do not appear to affect fertility, but higher amounts may cause impairment.
Exposure to environmental hazards (such as herbicides, pesticides, and industrial solvents) may affect fertility. Estrogen-like chemicals that interfere with normal hormones are of particular concern for infertility in men and for effects on offspring of women. Phthalates, chemicals used to soften plastics, are under particular scrutiny because they may disrupt hormones.
Stress and Fertility
Neurotransmitters (chemical messengers in the brain) act in the hypothalamus gland, which controls both reproductive and stress hormones. It is not clear if stress has any significant effect on fertility or fertility treatments. Several large studies indicate it does not.
Doctors recommend that both male and female partners get tested for infertility if pregnancy fails to occur after 1 year of regular unprotected sexual intercourse, or after 6 months if a woman is over age 35. (Most couples who do not have fertility problems conceive within the first 6 months of attempting pregnancy, and typically within the first 3 months.)
Fertility testing is particularly important if a woman is over 35 years old or if either partner has known risk factors for infertility. An analysis of the man's semen should be performed before the female partner undergoes any invasive testing.
Ovulation Home Tests
Before beginning an expensive fertility work-up, you can try the following steps at home. They are free or low-cost and may be helpful:
- Monitor basal body temperature. Basal body temperature (BBT) is the body’s temperature at rest. Basal means lowest. The BBT is the body’s natural lowest temperature, and it typically occurs upon awakening in the morning. Because BBT increases slightly (less than 0.5 degree Fahrenheit) during ovulation, tracking and charting your BBT may help you determine when ovulation takes place. You can monitor your BBT by taking your temperature at the same time every morning using a regular thermometer or a special digital BBT thermometer that stores and displays the data.
- Test the consistency of your cervical mucus. Collect some mucus between two fingers and stretch it apart. If you are near the time of ovulation, the mucus will stretch more than 1 inch before it breaks. As an alternative, at-home kits can test saliva as substitute for checking cervical mucus.
- Use an over-the-counter urine test to detect luteinizing hormone (LH) surges. This helps determine the day of ovulation. Tests are also available to measure levels of follicle-stimulating hormone (FSH). However, these at-home tests may not be as accurate as those performed in a doctor’s office.
Medical History and Physical Examination
The first step in any infertility work up is a complete medical history and physical examination. The doctor will ask about the patient's history of sexual activity, including frequency and timing of intercourse. Menstrual history, lifestyle issues (smoking, drug and alcohol use, and caffeine consumption), any medications being taken, and a profile of the patient's general medical and emotional health can help the doctor decide on appropriate tests.
Several laboratory tests may be used to detect the cause of infertility and monitor treatments.
Hormonal Levels. Blood and urine tests are taken to evaluate hormone levels. Hormonal tests for ovarian reserve (the number of follicles and quality of the eggs) are especially important for older women.
Examples of possible results include:
- High follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels and low estrogen levels suggest premature ovarian failure.
- High LH and low FSH may suggest polycystic ovary syndrome or luteal phase defect.
- High FSH and high estrogen levels on the third day of the cycle predict poor success rates in older women trying fertility treatments.
- LH surges indicate ovulation.
- Blood tests for prolactin levels and thyroid function are also measured. These are hormones that may indirectly affect fertility.
Clomiphene Challenge Test. Clomiphene citrate (Clomid, Serophene, generic), a standard fertility drug, may be used to test for ovarian reserve. With this test, the doctor measures FSH on day 3 of the cycle. The woman takes clomiphene orally on days 5 and 9 of the cycle. The doctor measures FSH on the tenth day. High levels of FSH either on day 3 or day 10 indicate a poor chance for a successful outcome.
Tissue Samples. To rule out luteal phase defect, premature ovarian failure, or absence of ovulation, the doctor may take tissue samples of the uterus 1 - 2 days before a period to determine if the corpus luteum is adequately producing progesterone. Samples taken from the cervix may be cultured to rule out infection.
Tests for Autoimmune Disease. Tests for autoimmune disease, such as hypothyroidism and type 1 diabetes, should be considered in women with recent ovarian failure that is not caused by genetic abnormalities.
Imaging Tests and Diagnostic Procedures
If an initial fertility work-up does not reveal abnormalities, more extensive tests may help reveal abnormal tubal or uterine findings. The four major approaches for examining the uterus and fallopian tubes are:
- Ultrasound (particularly a variation called saline-infusion sonohysterography)
Combinations of these imaging procedures may be used to confirm diagnoses.
Ultrasound and Sonohysterography. Ultrasound is the standard imaging technique for evaluating the uterus and ovaries. It is also used for detecting fibroids, ovarian cysts and tumors, and obstructions in the urinary tract. It uses sound waves to produce an image of the organs and causes very little discomfort.
Transvaginal sonohysterography uses ultrasound along with saline infused into the uterus, which enhances the visualization of the uterus. This technique can be more accurate than standard ultrasound in identifying potential problems. It is currently the gold standard for diagnosing polycystic ovaries.
Hysteroscopy. Hysteroscopy is a procedure that may be used to detect the presence of endometriosis, fibroids, polyps, pelvic scar tissue, and blockage at the ends of the fallopian tubes. Some of these conditions can be corrected during the procedure by cutting away any scar tissue that may be binding organs together or by destroying endometrial implants.
Hysteroscopy may be done in a doctor’s office or in an operating room, depending on the type of anesthesia used. The procedure uses a long flexible or rigid tube called a hysteroscope, which is inserted into the vagina and advanced through the cervix to reach the uterus. A fiber-optic light source and a tiny camera in the tube allow the doctor to view the cavity. The uterus is filled with saline or carbon dioxide to inflate the cavity and provide better viewing. This can cause cramping.
There are small risks of bleeding, infection, and reactions to anesthesia. Many patients experience temporary discomfort in the shoulders after the operation due to residual carbon dioxide that puts pressure on the diaphragm.
Hysterosalpingography. Hysterosalpingography is performed to discover possible blockage in the fallopian tubes and abnormalities in the uterus:
- The doctor inserts a tube into the cervix through which a special dye is injected. (The patient may experience some cramping and discomfort.)
- The dye passes into the uterus and up through the fallopian tubes.
- An x-ray is taken of the dye-filled uterus and tubes.
- If the dye is seen emerging from the end of the tube, no blockage is present. (In some cases, hysterosalpingography may even restore fertility by clearing away tiny tubal blockages.)
- If results show blockage or abnormalities, the test may need to be repeated. In case of blockage, hysterosalpingography may reveal a number of conditions, including endometrial polyps, fibroid tumors, or structural abnormalities of the uterus and tubes.
There is a small risk of pelvic infection, and antibiotics may be prescribed prior to the procedure.
Laparoscopy. Laparoscopy is a minimally invasive surgical procedure. It requires general anesthesia and is performed in an operating room. The surgeon makes a very small incision below the belly button and inserts an instrument called a laparoscope, which is similar to a hysteroscope. (The difference is that a laparoscope is inserted through the abdomen, while a hysteroscope is inserted through the vagina and cervix.) Through the laparoscope, the surgeon can view the uterus, fallopian tube, and ovaries. Laparoscopy is most helpful for identifying endometriosis or other adhesions that may affect fertility.
Treatment for infertility should first address any underlying medical condition that may be contributing to fertility problems. Drugs, surgery, or both may be used to treat these conditions. Surgery may also be used to repair blockage in fallopian tubes.
Fertility Treatment Approaches
Several approaches are used to treat infertility:
- Lifestyle measures (such as maintaining a healthy weight, quitting smoking, refraining from excessive alcohol use, timing sexual activity with ovulation cycle)
- Drugs to induce ovulation, such as clomiphene and gonadotrophins
- Assisted reproductive technologies (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
Choosing a Fertility Clinic
Some doctors recommend that if a couple fails to conceive after 1 - 2 years of frequent unprotected sex, they should consult a fertility expert. Women who are 35 or older, however, may want to begin exploring their options if they do not become pregnant within 6 months to a year.
Choosing a good fertility clinic is important. Those offering assisted reproductive techniques are not always regulated by the government, and abuses have been reported, including lack of informed consent, unauthorized use of embryos, and failure to routinely screen donors for disease.
The clinic should always provide the following information:
- The live-birth rate (not just pregnancy success rate) for other couples with similar infertility problems. (Multiple births, such as twins or triplets, are counted as one live birth.)
- Such statistics should include high-risk women, such as those who are older or fail to produce eggs. (Some disreputable clinics give success percentages that exclude high-risk women from their total, thereby making the percentage of success much higher.)
Advanced fertility procedures and medications are extremely expensive and often not covered by insurance. Couples should be cautious about offers of rebates in the event of failure; the clinics offering them are often significantly more expensive than those that don't offer such gimmicks.
Special Considerations for Patients with Cancer
Women who are undergoing cancer treatments and who want to become pregnant should see a reproductive specialist to discuss their options These discussions should take place as early as possible, and before cancer treatment starts.
According to the American Society of Clinical Oncology's guidelines, the best fertility preservation methods for female cancer patients are embryo and oocyte (egg) cryopreservation. This procedure involves harvesting and freezing a woman's eggs (oocytes), and can be followed by in vitro fertilization and freezing of embryos for later use. It requires several weeks of pre-treatment with ovarian stimulation drugs, so planning is very important.
Ovarian transposition, which involves moving one or both ovaries outside of the treatment field, may be an option for some women who are undergoing pelvic radiation. If you are going to be having gynecological surgery or radiation as part of your cancer treatment, discuss with your doctors any options for procedures that may help conserve fertility. And, be sure your doctors clearly explain to you how various cancer treatments could affect your fertility.
Embryo and oocyte cryopreservation are well-established methods that have excellent chances for success. At this time, other fertility preservation methods such as ovarian tissue cryopreservation, are still considered experimental and the American Society of Clinical Oncology does not recommend them.
Medications to treat infertility can be divided into three main categories:
- Medications for Ovarian Stimulation. These drugs are often used alone as initial treatment to induce ovulation, particularly for women who have medical conditions that cause irregular or dysfunctional ovulation. They may also be also used along with assisted reproductive technologies (ART), such as in vitro fertilization or intrauterine insemination, to stimulate multiple eggs to grow in the ovaries, a process called superovulation. The main drugs used for ovarian stimulation are clomiphene, (follicle stimulating hormone (FSH), luteneizing hormone (LH), and human menopausal gonadotrophin (hMG).
- Medications for Oocyte Maturation. Drugs such as human chorionic gonadotropin (hCG) are used during ART to help the ovarian follicles ripen (mature)
- Medications to Prevent Premature Ovulation. These drugs are used during ART to help prevent premature ovulation. They include GnRH agonists and GnRH antagonists.
Other drugs may also be used. For example, letrazole (Femara) is an aromatase inhibitor that is not approved for treatment of infertility but is often used “off-label” for ovarian stimulation.
Clomiphene citrate (Clomid, Serophene, generic) is usually the first fertility drug prescribed for women who have ovulation problems. (It is less likely to work for women who have normal ovulation.)
Unlike more potent drugs used in superovulation, clomiphene is gentler and works by blocking estrogen, which tricks the pituitary into producing follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This boosts follicle growth and the release of the egg. Clomiphene can be taken by mouth, is relatively inexpensive, and the risk for multiple births (about 5%, mostly twins) is lower than with other drugs.
One or two tablets are taken each day for 5 days, usually starting 2 - 5 days after the period starts. If successful, ovulation occurs about a week after the last pill has been taken. If ovulation does not occur, then a higher dose may be given for the next cycle.
If this regimen is not successful, treatment may be prolonged or additional drugs may be added. (Women who have polcystic ovarian syndrome often receive metformin in addition to clomiphene to help treat insulin resistance that may affecting their ovulation function.) Doctors usually do not recommend more than 6 cycles.
Mood swings are a very common side effect of clomiphene. Other side effects include hot flashes, breast tenderness, nausea, pelvic discomfort, and ovarian cysts.
If clomiphene does not work or is not an appropriate choice, gonadotropin drugs are a second option. Gonadotropins include several different types of drugs that contain either a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), or only FSH. Whereas clomiphene works indirectly by stimulating the pituitary gland to secrete FSH, (which prompts follicle production), gonadtropin hormones directly stimulate the ovaries to produce multiple follicles.
Gonadotropins are given by injection. (Your doctor may show you how to self-administer the injection.) Gonadotropins include:
- Human Menopausal Gonadtropins (hMG), also called menotropins
- Human Chorionic Gonadotropins (hCG)
- Follicle Stimulating Hormone (FSH)
- Gonadotropin-releasing hormone (GnRH) analogs, which include GnRH agonists and GnRH antagonists
Gonadotropin drugs are either natural compounds extracted from urine or synthetic compounds that are genetically engineered in a laboratory using recombinant DNA.
Human Menopausal Gonadotropin (hMG). HMG drugs, also called menotropins, contain a mixture of both FSH and LH. These drugs (Menopur, Repronex, Humegon) are all derived from the urine of postmenopausal women. HMG is administered as a series of injections 2 - 3 days after the period starts. Injections are usually given for 7 - 12 days, but the time may be extended if ovulation does not occur. In such cases, a shot of human chorionic gonadotropin (hCG) may trigger ovulation.
Human Chorionic Gonadotropin (hCG). Human chorionic gonadotropin (hCG) is similar to LH. It mimics the LH surge, which stimulates the follicle to release the egg. Natural hCG drugs, derived from the urine of pregnant women, include Pregnyl, Profasi, Novarel, and APL. Ovidrel is the only available genetically modified hCG drug. Ovidrel has fewer side effects at the injection site, and its quality can be better controlled than the natural drugs. It is generally used after hMG or FSH to stimulate the final maturation stages of the follicles. Ovulation, if it occurs, does so about 36 - 72 hours after administration.
Follicle Stimulating Hormone (FSH). Urofollitropin (Bravelle, Fertinex) is a purified form of FSH, derived from the urine of postmenopausal women. Follitropin drugs (Gonal-F, Follistim) are synthetic versions of FSH. These FSH drugs are sometimes given in combination with an hCG drug.
GnRH Analogs (Agonists or Antagonists). Gonadotropin-releasing hormone (GnRH) is a hormone produced in the hypothalamus part of the brain. GnRH stimulates the pituitary gland to produce LH and FSH. GnRH analogs are synthetic drugs that are classified as either agonists or antagonists. They are similar to natural GnRH but have very different actions. While natural GnRH stimulates LH and FSH, these drugs actually prevent the LH and FSH surge that occurs right before ovulation. This action helps prevent the premature release of the eggs before they can be harvested for assisted reproductive technologies.
- GnRH agonists include leuprolide (Lupron, generic), nafarelin (Synarel), and goserelin (Zoladex).
- GnRH antagonists include ganarelix (Antagon) and cetrorelix (Cetrotide). GnRH antagonists suppress FSH and LH more than GnRH agonists, and they may require fewer injections.
Risks of Superovulation
Superovulation is the process of using fertility drugs to stimulate the development of multiple follicles (eggs) in the ovaries. Superovulation is also called controlled ovarian stimulation.
Potential risks and complications of superovulation include:
- Multiple Births. Superovulation increases the risks for multiple births, approximately 20% for twins and 2 - 5% for triplets. The exact risks depend in part on the drug used and whether it is used along with ART.
- Ovarian Hyperstimulation Syndrome. The most serious risk of superovulation is ovarian hyperstimulation syndrome (OHSS), a condition in which the ovaries become enlarged and filled with fluid. In severe cases, this can lead to life-threatening complications including blood clots, liver and kidney damage, and dangerous fluid and electrolyte imbalances. Symptoms include abdominal bloating and pain, weight gain, nausea and vomiting, and shortness of breath.
- Cancer Concerns. There has been concern that clomiphene and gonadotropins may increase the risks for ovarian and breast cancer. Most evidence to date does not indicate that ovulation-stimulating drugs increase the risks for these types of cancers. Some studies suggest that clomiphene, which is chemically related to the breast cancer drug tamoxifen, may actually decrease the risk for breast cancer.
Assisted Reproductive Technologies
Assisted reproductive technologies (ART) are medical techniques that help couples conceive. These procedures involve either:
- A couple’s own eggs or sperm
- Donor eggs, sperm, or embryos
Fertilization may occur either in the laboratory or in the uterus. In the U.S., the number of live birth deliveries from ART has doubled in the last decade. About 48,000 live births (deliveries of one or more infants) occur in the U.S. each year using assisted reproductive technologies. According to the Centers for Disease Control (CDC), over 1% of all babies born in the United States every year are conceived using ART.
Technically, the term ART refers only to fertility treatments, such as in vitro fertilization (IVF) and its variants, which handle both egg and sperm.
Intrauterine Insemination (IUI)
Artificial insemination (AI) involves placing the sperm directly in the cervix (called intracervical insemination) or into the uterus (called intrauterine insemination, or IUI).
IUI is the standard AI procedure. It involves placing washed sperm into the woman’s uterine cavity through a long, thin catheter. The procedure is performed when a woman is ovulating and is used for patients whose tubes are not blocked from endometriosis or scarring.
- A woman will first be given three cycles of clomiphene pills to stimulate egg production, at the same time having sexual contact with her partner timed around ovulation.
- If she fails to conceive, three additional cycles of clomiphene are used, combined with IUI.
- If the clomiphene-IUI combination does not work, the woman receives three cycles of IUI combined with injections of a gonadotropin-stimulating hormone drug.
- If this method fails, the woman may be a candidate for in vitro fertilization (IVF). Some insurance plans only cover IUI and do not pay for IVF.
IUI is the least complex and least expensive of fertility procedures and is often tried first in uncomplicated cases of infertility. However, it may pose a greater risk for multiple births and have a lower chance for pregnancy success than IVF. For these reasons, some doctors recommend that couples who fail to conceive after three cycles of clomiphene-IUI proceed directly to IVF.
In Vitro Fertilization (IVF)
Most assisted reproductive technologies procedures use in vitro fertilization (IVF). An in vitro procedure is one that is performed in the laboratory. Advances in these procedures have dramatically increased the rate of live births. IVF can be performed with a woman’s own eggs and sperm, or with donor eggs and sperm.
In the past, IVF was used mainly to treat women with damaged fallopian tubes. It is now used as a fertility treatment for cases when the woman has endometriosis, the man has fertility problems, or the cause of a couple’s infertility is unexplained.
A standard IVF cycle is divided into the following steps:
- Ovarian Suppression. The patient receives treatment with either a GnRH agonist (Lupron) or GnRH antagonist (Antagon, Cetrotide). Sometimes birth control pills are given as pre-treatment. The purpose is to prevent premature ovulation and make sure that the follicles will ripen at the same time.
- Ovarian Stimulation. Ovarian-stimulating drugs, such as clomiphene, FSH, or LH, are used to prompt the ovaries to produce multiple eggs. The patient receives ultrasounds to monitor the growth of egg follicles and blood tests to check hormone levels. A cycle may be canceled if not enough follicles are produced or if there is a risk of ovarian hyperstimulation syndrome (see Medications section).
- HCG Trigger Injection. About 8 - 14 days later, an injection of human chorionic gonadotropin (hCG) is given to foster egg maturation. The timing of this shot is very important for the success of the IVF procedure.
- Egg Retrieval. About 34 - 36 hours after the hCG injection, the eggs are retrieved. To retrieve the eggs, the doctor inserts an ultrasound-guided probe into the vagina. A needle is then used to drain the liquid from the follicles, and several eggs are retrieved. The woman begins taking progesterone or another type of medication to help prepare the lining of the uterus to support the embryo.
- Fertilization and Embryo Culture. The doctor will examine the eggs to evaluate their quality and maturity. Selected eggs are placed in a culture in the laboratory and transferred to an incubator. They are then inseminated with sperm, either by placing sperm together with the egg or injecting a single sperm into the egg (see ICSI section below).
- Embryo Transfer and Cryopreservation. One or more embryos are implanted in the woman’s uterus 2 - 6 days after egg retrieval. The doctor will discuss with the patient the appropriate number of embryos to be implanted. Excess embryos may be frozen and saved for future use. (The live birth rate is usually lower with cryopreserved embryos.) It takes about 9 - 12 days to determine if pregnancy has been achieved.
Embryo Transfer Guidelines. In 2013, the American Society for Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technologies (SART) updated its joint guidelines on the number of embryos that should be transferred during IVF procedures. The new guidelines include distinctions between cleavage-stage (2 - 3 days after fertilization) and blastocyst (5 - 6 days after fertilization) embryos.
The guidelines recommend:
- For women under the age of 35, a single embryo transfer or no more than 2 embryos (either cleavage-stage or blastocyst)
- For women between ages 35 - 37, no more than 2 cleavage-stage embryos
- For women between ages 38 - 40, no more than 3 cleavage-stage embryos or 2 blastocysts
- For women ages 41 - 42, no more than 5 cleavage-stage embryos or 3 blastocysts
- For women older than age 43, there are insufficient data to recommend a limit on the number of embryos
These embryo numbers are recommended for women with favorable prognoses. For patients who have failed to become pregnant after at least two IVF cycles, or who have a less favorable prognosis, the doctor may consider adding one additional embryo. The guidelines apply to both fresh and frozen embryos.
Other IVF Procedures. Some IVF procedures use adaptations called gamete intrafallopian transfer (GIFT) and zygote intrafallopian transfer (ZIFT), which transfers the gametes (egg and sperm) into a women’s fallopian tube rather than her uterus. In GIFT, the egg is harvested as with IVF and mixed with sperm, and is then injected into the woman’s fallopian tube where fertilization occurs. In ZIFT, the egg is fertilized with sperm in the laboratory before being transferred to the fallopian tube. For GIFT and ZIFT a woman must have at least one functioning fallopian tube.
Success Rates. Not all IVF cycles result in pregnancy, and not all IVF-achieved pregnancies result in live births. When a woman’s own eggs are used, results are better with fresh embryos than frozen embryos. According to the most recent statistics from the U.S. Centers for Disease Control (CDC), about 29% of ART cycles (mostly IVF) with fresh embryos resulted in a live birth of one or more babies. Success rates provided by fertility clinics are not always a reliable indicator as they depend on many variables, especially the age of the woman.
Data indicate that the chances of ART resulting in live birth are about:
- 40% for women younger than age 35
- 30% for women ages 35 - 37
- 20% for women ages 38 - 40
- 10% for women ages 41 - 42
- 5% for women ages 43 - 44
Some women try acupuncture during an IVF cycle to increase their chances for pregnancy success. While acupuncture is not harmful, there is no conclusive evidence that it boosts success rates.
Complications. Data have been conflicting on whether IVF increases the risk for genetic abnormalities and birth defects. In general, the overall risks for birth defects appear to be small. Studies indicate that most children conceived through IVF are healthy and have normal cognitive development and school performance.
The main risk of IVF is the consequences of multiple pregnancies. Multiple pregnancies increase the risks for a mother and her babies. In particular, there is increased risk for premature delivery and low birth weight. These factors can cause heart and lung problems and developmental disabilities in children.
Intracytoplasmic Sperm Injection (ICSI)
Intracytoplasmic sperm injection (ICSI) is an assisted reproductive technology used for couples when male infertility is the main problem. It involves injecting a single sperm into an egg obtained from in vitro fertilization (IVF). The procedure is very simple:
- A tiny glass tube (called a holding pipet) stabilizes the egg.
- A second glass tube (called the injection pipet) is used to penetrate the egg's membrane and deposit a single sperm into the egg.
- The egg is released into a drop of cultured medium.
- If fertilized, the egg is allowed to develop for 1 - 2 days, then it is either frozen or implanted.
The greatest concern with this procedure has been whether it increases the risk for birth defects. Many, but not all, studies have reported no higher risks of birth defects in children born using ICSI procedures. However, if the father’s infertility was due to genetic issues, this genetic defect may be passed on to male children conceived through ICSI.
Another concern has been whether the ICSI procedure is being overused. Some doctors recommend ICSI for women who have failed prior IVF attempts or who have few or poor-quality eggs, even if their male partners have normal semen measurements. According to the Society for Assisted Reproductive Technology, there is little evidence that ICSI helps improve pregnancy success for couples who do not have a problem with male factor infertility.
Although there are no dietary or nutritional cures for infertility, a healthy lifestyle is important. Some ovulatory problems may be reversible by changing behavioral patterns. Some tips include:
- Maintain a healthy weight. Women who are either over- or underweight are at risk for fertility failure, including a lower chance for achieving success with fertility procedures.
- Stop smoking. Smoking adversely affects infertility in both men and women. Everyone should quit.
- Avoid excessive exercise if it causes menstrual irregularity. However, moderate and regular exercise is essential for good health.
- Limit excessive caffeine and alcohol consumption. High levels of alcohol and caffeine are associated with decreased fertility.
- Avoid most commercial water-based sexual lubricants (Astroglide, KY Jelly). They can interfere with sperm motility and survival.
- Avoid any unnecessary medications.
Planning Sexual Activity
The “Fertile Window”. Couples can optimize their chances for conception by planning sexual intercourse during the woman’s fertile window:
- The so-called "fertile window" is 6 days long, starts 5 days before ovulation, and ends the day of ovulation.
- In a woman with a 28-day menstrual cycle, ovulation usually occurs around day 14 (14 days after the start of her menstrual period), which means the fertile window occurs from days 9 - 14. However, the length of menstrual cycles – and fertile windows -- vary from woman to woman.
- The chances for intercourse resulting in pregnancy are considered to be highest during the fertile window and especially on the 3-day interval that ends on the day of ovulation. Fertility doctors recommend having sex every 1 - 2 days during the fertile window.
In addition to tracking their menstrual cycle, women can try methods such as charting basal body temperature to monitor ovulation (see Diagnosis section of this report). This method is not always successful, but it may when combined with other approaches.
Frequency of Intercourse. Evidence indicates that chances are best for conception when sexual intercourse occurs every 1 - 2 days, especially during the fertile window. Less frequent sexual intercourse (2 - 3 times a week) also achieves good results. However, couples need to make their own personal choices about what amount of sexual activity is appropriate, comfortable, and desirable. Data suggest that abstinence (not having sex) of more than 5 - 10 days may adversely affect sperm health.
Sexual Practices. There's no evidence that any particular sexual positions, or resting after sex, help increase the chances for pregnancy. There’s also no evidence that whether or not a woman achieves orgasm affects the likelihood of her becoming pregnant. Couples should be aware that water-based vaginal lubricants (Astroglide, KY Jelly, saliva) can damage sperm’s ability to swim and should not be used. For lubrication, try mineral oil, canola oil, or commercially available “fertility friendly” products such as Pre-Seed, which do not harm sperm.
Dealing with Stress
The fertility treatment process presents a roller coaster of emotions. There are almost no sure ways to predict which couples will eventually conceive. Some couples with multiple problems will overcome great odds, while other, seemingly fertile, couples fail to conceive. Many of the new treatments are remarkable, but a live birth is never guaranteed. The emotional burden on the couple is considerable, and some planning is helpful.
- Decide in advance how many and what kind of procedures will be emotionally and financially acceptable and attempt to determine a final limit. Fertility treatments are expensive. A successful pregnancy often depends on repeated attempts.
- Prepare for multiple births as a possible outcome for successful pregnancy (especially if assisted reproductive technologies are used). A pregnancy that results in a multiple birth introduces new complexities and emotional problems
- Determine alternatives (adoption, donor sperm or egg, or having no children) as early as possible in the fertility process. This can reduce anxiety during treatments and feelings of disappointment in case conception does not occur.
On a reassuring note, a large study of infertile women indicated that stress levels do not affect the outcome of fertility treatments. The study found no difference in stress levels between women who became pregnant and those who did not. Women who are feeling stressed by problems with fertility or the challenges of the fertility treatment process should not feel additionally concerned that their emotional state may affect their chances of becoming pregnant.
- www.asrm.org -- American Society for Reproductive Medicine
- www.sart.org -- Society for Assisted Reproductive Technology
- www.theafa.org -- American Fertility Association
- www.acog.org -- American College of Obstetricians and Gynecologists
- www.cdc.gov/reproductivehealth/index.htm -- Centers for Disease Control: Assisted Reproductive Technology Reports
Boivin J, Griffiths E, Venetis CA. Emotional distress in infertile women and failure of assisted reproductive technologies: meta-analysis of prospective psychosocial studies. BMJ. 2011 Feb 23;342:d223.
Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2011 Assisted Reproductive Technology Fertility Clinic Success Rates Report. Atlanta (GA): US Dept of Health and Human Services; 2013.
Davies MJ, Moore VM, Willson KJ, Van Essen P, Priest K, Scott H, et al. Reproductive technologies and the risk of birth defects. N Engl J Med. 2012 May 10;366(19):1803-13. Epub 2012 May 5..
El-Toukhy T, Sunkara SK, Khairy M, Dyer R, Khalaf Y, Coomarasamy A. A systematic review and meta-analysis of acupuncture in in vitro fertilisation. BJOG. 2008 Sep;115(10):1203-13. Epub 2008 Jul 23.
ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update. 2009 May-Jun;15(3):265-77. Epub 2009 Feb 23.
Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med. 2011 Oct 6;365(14):1304-14.
Hudson MM. Reproductive outcomes for survivors of childhood cancer. Obstet Gynecol. 2010 Nov;116(5):1171-83.
Jain T, Gupta RS. Trends in the use of intracytoplasmic sperm injection in the United States. N Engl J Med. 2007 Jul 19;357(3):251-7.
Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ. 2009 Feb 5;338:b249.
Jensen JR, Morbeck DE, Coddington CC 3rd. Fertility preservation. Mayo Clin Proc. 2011 Jan;86(1):45-9.
Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1400-7. Epub 2007 Jun 21.
Lobo RA. Infertility: Etiology, diagnostic evaluation, management, prognosis. In: Lentz GM, Lobo RA, Gershenson DM, Katz VI, eds. Comprehensive Gynecology. 6th ed. Mosby Elsevier; 2012:chap 41.
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jul 1;31(19):2500-10. Epub 2013 May 28.
Luke B, Brown MB, Wantman E, Lederman A, Gibbons W, Schattman GL, et al. Cumulative birth rates with linked assisted reproductive technology cycles. N Engl J Med. 2012 Jun 28;366(26):2483-91.
Mains L, Zimmerman M, Blaine J, Stegmann B, Sparks A, Ansley T, et al. Achievement test performance in children conceived by IVF. Hum Reprod. 2010 Oct;25(10):2605-11. Epub 2010 Aug 17.
Manheimer E, Zhang G, Udoff L, Haramati A, Langenberg P, Berman BM, Bouter LM. Effects of acupuncture on rates of pregnancy and live birth among women undergoing in vitro fertilisation: systematic review and meta-analysis. BMJ. 2008 Mar 8;336(7643):545-9. Epub 2008 Feb 7.
Practice Committee of American Society for Reproductive Medicine; Practice Committee of Society for Assisted Reproductive Technology. Criteria for number of embryos to transfer: a committee opinion. Fertil Steril. 2013 Jan;99(1):44-6. Epub 2012 Oct 22.
Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Reproductive Endocrinology and Infertility. Fertil Steril. 2013 Sep;100(3):631-7. Optimizing natural fertility: a committee opinion.
Practice Committee of the American Society for Reproductive Medicine. Smoking and infertility: a committee opinion. Fertil Steril. 2012 Dec;98(6):1400-6. Epub 2012 Sep 6.
Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril. 2013 Aug;100(2):341-8. Epub 2013 Jun 27.
Williams CL, Bunch KJ, Stiller CA, Murphy MF, Botting BJ, Wallace WH, et al. Cancer risk among children born after assisted conception. N Engl J Med. 2013 Nov 7;369(19):1819-27.
Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril. 2009 Nov;92(5):1520-4. Epub 2009 Oct 14.
Review Date: 12/21/2013
Reviewed By: Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.